Biogen Idec Inc. (BIIB)’s Clean Bill of Health
From Insider Monkey - Free Hedge Fund and Insider Trading Data
January 29, 2013 - 10:25am
It’s crunch time for Biogen Idec Inc. (NASDAQ:BIIB) investors. With the company preparing for the Food and Drug Administration’s decision on its novel oral multiple sclerosis treatment, BG-12, Biogen first had to make its way through the hurdles of earnings season. The company’s financials performed well through the first nine months of 2012, but investors finally [...]
Continue reading this article »Share This Article: